Zydus Cadila Healthcare has received US Food and Drug Administrator's (FDA) approval for a drug used in the treatment of rheumatoid arthritis.

Zydus Cadila Healthcare has received an approval from FDA for the new Disease Modifying Anti-Rheumatic Drug (DMARD) Hydroxychloroquine Sulfate tablets of 200 mg strength. DMARD is a medication for patients with Rheumatoid Arthritis that helps decrease pain and inflammation, prevents joint damage and preserves the structure of the joints. Drugs of this category provide relief over a period of time ranging from a few weeks to a few months. The company would market the drug through its US-based subsidiary Zydus Pharmaceuticals (USA) Inc.